---

26 July 2007 : Column 1277W—continued

Cancer: Anaemia

Dr. Iddon: To ask the Secretary of State for Health what estimate his Department has made of the economic cost of working days lost due to cancer-related anaemia and fatigue. [152021]

26 July 2007 : Column 1278W

Ann Keen: The Department has made no estimate of the economic cost of working days lost due to cancer-related anaemia and fatigue.

Cancer: Drugs

Lynne Jones: To ask the Secretary of State for Health pursuant to the answer of 10 July 2007, Official Report, columns 1437-40W, on cancer: drugs, what the date of licence in the UK was for each drug. [152435]

Dawn Primarolo: The following table shows the date on which each specific indication was authorised (information current at 24 July 2007).

26 July 2007 : Column 1279W

26 July 2007 : Column 1280W

Condition and Drugs	Date of authorisation for specific indication	Drug substance	Notes
Aggressive non-Hodgkin's lymphoma—rituximab (MabThera)	Specific indication is not licensed	Rituximab	MabThera is licensed for the treatment of patients with CD20 positive diffuse large B cell non-Hodgkin's lymphoma.
Breast cancer—docetaxel (Taxotere)	28 August 2000	Docetaxel	First line treatment for advanced or metastatic breast cancer
Breast cancer—paclitaxel (Taxol)	27 March 2000	Paclitaxel
Breast cancer bevacizumab (Avastin)	27 March 2007	Bevacizumab
Breast cancer (advanced or metastatic)—lapatinib (Tyverb)	Drug substance not licensed	Lapatinib
Breast cancer (advanced)—tratuzumab (Herceptin)	28 August 2000	Tratuzumab
Breast cancer (advanced)—vinorelbine (Navelbine)	10 May 1996	Vinorelbine
Breast cancer (early)—anastrozole (Arimidex)	29 October 2002	Anastrozole
Breast cancer (early)—docetaxel (Taxotere)	Specific indication is not licensed	Docetaxel	Current licence is for advanced or metastatic breast cancer
Breast cancer (early)—exemastane (Aromasin)	26 August 2005	Exemastane
Breast cancer (early)—letrozole (Femara)	9 September 2004	Letrozole
Breast cancer (early)—paclitaxel (Taxol)	Specific indication is not licensed	Paclitaxel	Current licence is for advanced or metastatic breast cancer
Breast cancer (early)—trastuzumab (Herceptin)	22 May 2006	Trastuzumab
Breast cancer (locally advanced)—capecitabine (Xeloda)	21 March 2002	Capecitabine
Chronic lymphocytic leukaemia—fludarabine (Fludara)	11 August 1994	Fludarabine
Chronic myeloid leukaemia—imatinib (Glivec)	7 November 2001	Imatinib
Colon cancer (adjuvant)—capecitabine (Xeloda)	30 March 2005	Capecitabine
Colon cancer (adjuvant)—irinotecan (Campto)	Specific indication is not licensed	Irinotecan	Not licensed for adjuvant treatment
Colon cancer (adjuvant)—oxaliplatin (Eloxatin)	18 October 2004	Oxaliplatin
Colorectal cancer (advanced)==irinotecan (Campto)	14 July 1999	Irinotecan
Colorectal cancer (advanced)—oxaliplatin (Eloxatin)	23 August 1999	Oxaliplatin
Colorectal cancer (advanced)—ralitrexed (Tomudex)	11 August 1995	Ralitrexed
Colorectal cancer (metastatic)—capecitabine (Xeloda)	2 February 2001	Capecitabine
Colorectal cancer (metastatic)—tegafur + uracil (Uftoral)	5 January 2001	Tagafur + uracil
Follicular lymphoma—rituximab (MabThera)	2 June 1998	Rituximab
Gastro-intestinal stromal tumours (GIST)—imatinib (Glivec)	7 November 2001	Imatinib
Glioblastoma multiforme (recurrent)—carmustine (Gliadel)	28 September 2000	Carmustine
Glioma (newly diagnosed and high-grade)—carmustine (Gliadel)	14 December 2004	Carmustine
Glioma (newly diagnosed and high-grade)—temozolomide (Temodal)	21 April 2005	Temozolomide
Head & neck cancer—cetuximab (Erbitux)	29 March 2006	Cetuximab
Lung cancer (non small cell)—bevacizumab (Avastin)	Specific indication is not licensed	Bevacizumab	Not licensed for lung cancers of any type
Lung cancer (non small cell)—erlotinib (Tarceva)	19 September 2005	Erlotinib
Lung cancer (non small cell)—gefitinib (Iressa)	Not licensed	Gefitinib	Drug substance not licensed
Lung cancer (non small cell)—pemetrexed (Alimta)	20 September 2004	Pemetrexed
Lung cancer (non-small cell)—paclitaxel (Taxol)	18 November 1998	Paclitaxel
Lung cancer (non-small cell) docetaxel (Taxotere)	20 January 2000	Docetaxel
Lung cancer (non-small cell) gemcitabine (Gemzar)	26 April 2000	Gemcitabine
Lung cancer (non-small cell) vinorelbine (Navelbine)	10 May 1996	Vinorelbine
Mesothelioma pemetrexed (Alimta)	20 September 2004	Pemetrexed
Metastatic breast cancer—gemcitabine (Gemzar)	25 November 2004	Gemcitabine
Metastatic colorectal cancer—bevacizumab (Avastin)	12 January 2005	Bevacizumab
Metastatic colorectal cancer—cetuximab (Erbitux)	24 June 2004	Cetuximab
Non-Hodgkin's Lymphoma—rituximab (MabThera)	21 March 2002	Rituximab
Ovarian cancer—paclitaxel (Taxol)	11 October 1996 (for first line treatment of advanced ovarian cancer)	Paclitaxel	Original licence was for second-line treatment only
Ovarian cancer—pegylated liposomal doxorubicin (Caelyx)	24 October 2000	Doxorubicin
Ovarian cancer (advanced)— topotecan (Hycamtin)	12 November 1996	Topotecan
Pancreatic cancer gemcitabine (Gemzar)	30 October 1996	Gemcitabine
Pancreatic cancer—Rubetican	Not licensed	Rubetican	Drug substance not licensed
Prostate cancer Atrasentan	Not licensed	Atrasentan	Drug substance not licensed
Prostate cancer—docetaxel (Taxotere)	6 February 2004	Docetaxel
Recurrent malignant glioma—temozolomide (Temodal)	20 January 1999	Temozolomide
Relapsed multiple myeloma—bortezomib (Velcade)	26 April 2004	Bortezomib
Renal cell carcinoma—bevacizumab (Avastin)	Specific indication is not licensed	Bevacizumab	Substance not licensed for renal cancers
Renal cell carcinoma—sorafenib tosylate (Nexavar)	29 July 2004	Sorafenib tosylate
Renal cell carcinoma—sunitinib (Sutent)	11 January 2007	Sunitinib

Cardiovascular System: Screening

Dr. Naysmith: To ask the Secretary of State for Health what progress has been made in identifying a suitable risk assessment engine to calculate cardiovascular risk in patients in England and Wales; and what consideration has been given to the importance of including waist circumference for assessment by such a tool. [152178]

Ann Keen: Recent publications by the Scottish Intercollegiate Guidelines Network and by the QResearch group, the latter in the British Medical Journal, have outlined new approaches to cardiovascular risk assessment. These publications offer significant contribution to the debate that will now take place as a result of the National Institute for Health and Clinical Excellence’s recent publication of draft clinical guidelines on lipid modification, which covers cardiovascular risk assessment. The Department is monitoring this debate with interest.

Dr. Naysmith: To ask the Secretary of State for Health (1) what the reasons are for the delay in his Department’s Vascular Programme and guidance on vascular assessment; and when he expects this to be published; [152179]

(2) what steps he is taking to ensure that the guidance on vascular risk assessment being prepared by his Department will be implemented successfully at primary care level. [152361]

26 July 2007 : Column 1281W

Ann Keen: The Department has made no commitment to publish guidance on vascular risk assessment. There has been no delay in the publication of such guidance.

The Department’s Vascular Programme Board has been giving careful consideration to the potential benefits of a more integrated approach to vascular risk assessment and management. This is a complex area, which requires further study particularly in the light of the National Institute for Health and Clinical Excellence’s recently published draft guidance on lipid modification, which covers cardiovascular risk assessment.

---